XML 14 R4.htm IDEA: XBRL DOCUMENT v3.7.0.1
Condensed Consolidated Statements of Operations - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 9 Months Ended
Mar. 31, 2017
Mar. 31, 2016
Mar. 31, 2017
Mar. 31, 2016
Income Statement [Abstract]        
Molecular diagnostic testing $ 185.2 $ 177.4 $ 534.2 $ 532.0
Pharmaceutical and clinical services 11.7 13.1 36.7 35.4
Total revenue 196.9 190.5 570.9 567.4
Costs and expenses:        
Cost of molecular diagnostic testing 37.9 33.6 109.5 98.6
Cost of pharmaceutical and clinical services 6.4 6.6 19.1 18.7
Research and development expense 17.6 17.2 55.6 51.1
Selling, general, and administrative expense 122.1 90.5 354.3 267.8
Total costs and expenses 184.0 147.9 538.5 436.2
Operating income 12.9 42.6 32.4 131.2
Other income (expense):        
Interest income 0.3 0.3 0.9 0.5
Interest expense (1.5)   (4.8) (0.2)
Change in the fair value of contingent consideration (5.2)   (2.0)  
Other 1.5 0.2 (2.4) 0.2
Total other income (expense): (4.9) 0.5 (8.3) 0.5
Income before income tax 8.0 43.1 24.1 131.7
Income tax provision 3.8 8.6 15.2 29.7
Net income 4.2 34.5 8.9 102.0
Net loss attributable to non-controlling interest 0.0 0.0 (0.1) 0.0
Net income attributable to Myriad Genetics, Inc. stockholders $ 4.2 $ 34.5 $ 9.0 $ 102.0
Earnings per share:        
Basic $ 0.06 $ 0.49 $ 0.13 $ 1.46
Diluted $ 0.06 $ 0.47 $ 0.13 $ 1.39
Weighted average shares outstanding:        
Basic 68.1 70.9 68.1 70.1
Diluted 68.3 73.5 68.5 73.2